Literature DB >> 14955779

Pharmacological properties of benzazoles. I. Relationship between structure and paralyzing action.

E F DOMINO, K R UNNA, J KERWIN.   

Abstract

Entities:  

Keywords:  MUSCLE RELAXANTS

Mesh：

Substances：

Year:  1952        PMID： 14955779

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN： 0022-3565            Impact factor:   4.030


× No keyword cloud information.
  10 in total

1.  [Benzimidazole derivatives with strong analgesic effects].

Authors:  F GROSS; H TURRIAN
Journal:  Experientia       Date:  1957-10-15

2.  Improvement of endothelium-dependent vasodilations by SKA-31 and SKA-20, activators of small- and intermediate-conductance Ca2+ -activated K+ -channels.

Authors:  A-L Hasenau; G Nielsen; C Morisseau; B D Hammock; H Wulff; R Köhler
Journal:  Acta Physiol (Oxf)       Date:  2011-03-01       Impact factor: 6.311

3.  Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure.

Authors:  Ananthakrishnan Sankaranarayanan; Girija Raman; Christoph Busch; Tim Schultz; Pavel I Zimin; Joachim Hoyer; Ralf Köhler; Heike Wulff
Journal:  Mol Pharmacol       Date:  2008-10-27       Impact factor: 4.436

4.  The activity of a variety of chemical compounds against experimental tetanus.

Authors:  D R LAURENCE; R A WEBSTER
Journal:  Br J Pharmacol Chemother       Date:  1958-09

5.  Centrally acting muscle relaxants in tetanus.

Authors:  R A WEBSTER
Journal:  Br J Pharmacol Chemother       Date:  1961-12

6.  The neuroprotective drug riluzole acts via small conductance Ca2+-activated K+ channels to ameliorate defects in spinal muscular atrophy models.

Authors:  Maria Dimitriadi; Min Jeong Kye; Geetika Kalloo; Jill M Yersak; Mustafa Sahin; Anne C Hart
Journal:  J Neurosci       Date:  2013-04-10       Impact factor: 6.167

Review 7.  From Riluzole to Dexpramipexole via Substituted-Benzothiazole Derivatives for Amyotrophic Lateral Sclerosis Disease Treatment: Case Studies.

Authors:  Serge Mignani; Jean-Pierre Majoral; Jean-François Desaphy; Giovanni Lentini
Journal:  Molecules       Date:  2020-07-22       Impact factor: 4.411

8.  Rethinking to riluzole mechanism of action: the molecular link among protein kinase CK1δ activity, TDP-43 phosphorylation, and amyotrophic lateral sclerosis pharmacological treatment.

Authors:  Maicol Bissaro; Stefano Moro
Journal:  Neural Regen Res       Date:  2019-12       Impact factor: 5.135

9.  Developing Novel Therapies for Degenerative Cervical Myelopathy [AO Spine RECODE-DCM Research Priority Number 7]: Opportunities From Restorative Neurobiology.

Authors:  Aref-Ali Gharooni; Brian K Kwon; Michael G Fehlings; Timothy F Boerger; Ricardo Rodrigues-Pinto; Paul Aarne Koljonen; Shekar N Kurpad; James S Harrop; Bizhan Aarabi; Vafa Rahimi-Movaghar; Jefferson R Wilson; Benjamin M Davies; Mark R N Kotter; James D Guest
Journal:  Global Spine J       Date:  2022-02

10.  6-Meth-oxy-1,3-benzothia-zol-2-amine.

Authors:  Aamer Saeed; Hummera Rafique; Ulrich Flörke
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-06-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.